Regeneron Pharmaceuticals Details C5 Strategy, With PNH Data Due Q4 and gMG NDA Under Review

Regeneron Pharmaceuticals outlined its C5 complement development strategy, highlighting the combination of cemdisiran and pozelimab to achieve tunable complement inhibition for conditions like PNH, gMG, and GA. Key clinical catalysts include PNH data due in Q4 and an FDA decision for gMG also expected in Q4 2026. The company views this C5 franchise as a multi-indication, multi-billion-dollar opportunity, with gMG as the immediate priority.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin